Dendritic Cells in Human Renal Inflammation - Part II by Noessner, Elfriede et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Minireview 
 Nephron Exp Nephrol 2011;119:e91–e98  
 DOI: 10.1159/000332032 
 Dendritic Cells in Human Renal 
Inflammation – Part II 
 Elfriede Noessner a    Maja Lindenmeyer c    Peter J. Nelson b    Stephan Segerer c, d 
 a  Institute of Molecular Immunology, Helmholtz Zentrum München, German Research Center for Environmental 
Health, and  b  Medizinische Poliklinik-Innenstadt, University of Munich,  Munich , Germany;  c  Division of Nephrology, 
University Hospital Zurich, and  d  Institute of Anatomy, University of Zurich,  Zurich , Switzerland 
ciation with the collecting ducts and urothelium. A function-
al characterization of these subtypes has been hampered by 
the difficulty of obtaining samples for analysis. However, 
these studies are clearly required to define the role of DCs 
and DC subsets in the pathophysiology of renal disease. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction  
 Dendritic cells (DCs) are a potent class of antigen-pre-
senting cells that control the initiation and progression of 
immune responses  [1, 2] . They play an important role in 
moderating the balance between tolerance and immu-
nity  [3, 4] . The general biology of DCs and their subsets 
and the role of DCs in experimental renal inflammation 
are discussed by Lindenmeyer et al. [5] in this issue. Here, 
we focus on the current status of DC biology in human 
renal disease. 
 Human DC Subsets 
 Due to the lack of a specific marker, the definition of 
DCs and their distinction from monocyte/macrophages 
is difficult in humans. In the mouse, CD11c is an accept-
able marker for the identification of DCs. However, in 
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 Abstract 
 Dendritic cells (DCs) are bone marrow-derived professional 
antigen-presenting cells that act as master regulators of ac-
quired and innate immune responses. Here, we review the 
available information on their role in human renal inflamma-
tion. In the 1980s and early 1990s, major histocompatibility 
complex class II antigen- (HLA-DR) positive DCs were first 
described in normal human kidneys and in the interstitium 
of kidneys from patients with glomerulonephritis. Several 
DC subtypes were subsequently distinguished based on 
their expression of CD1c/BDCA-1, CD141/BDCA-3 and CD209/
DC-SIGN (in combination with HLA-DR). These cells were 
almost exclusively found in the tubulointerstitium, with 
increased numbers seen during glomerulonephritis. It ap-
pears that the human renal tubulointerstitium harbors dif-
ferent DC types which allow the collection of both exoge-
nous as well as endogenous antigens. Plasmacytoid DCs 
have a plasma cell-like morphology and were commonly 
found within nodular tubulointerstitial infiltrates. Follicular 
DCs are rarely seen, but show a predominant localization in 
organized infiltrates. CD207/langerin is a marker for Langer-
hans cells. Langerin-positive cells have been found in asso-
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humans, CD11c is also expressed by nearly all monocytes 
and macrophages. Moreover, the observation that mono-
cytes can readily differentiate into DCs in vitro and in 
vivo and that DCs from the peripheral blood can also dif-
ferentiate into macrophages supports the contention that 
the macrophage/DC association is a continuum rather 
than a collection of defined cell types  [6–9] . The different 
types of human DCs as defined by their most common 
markers and proposed functions are illustrated in  table 1 
and  figure 1 . As more is learned about these cells, the col-
lection of DC subtypes and their markers will likely be 
expanded in the near future.
 DC subsets in humans have been readily characterized 
in the blood using the markers CD1c/BDCA-1, CD303/
BDCA-2, CD141/BDCA-3 and CD204/BDCA-4  [10, 11] . 
These markers are not expressed in the same way in mice, 
which complicates a direct comparison of DC subsets be-
tween mouse and man. 
 Human plasmacytoid DCs (pDCs) are distinguished 
from myeloid DCs by their expression of CD303/BDCA-2 
and CD304/BDCA-4, and the absence of the common 
myeloid markers CD68, CD13 and CD33. Myeloid DCs 
are CD13 and CD33 positive, and can be further subdi-
vided into conventional (monocyte-independent) DCs 
(cDCs) and monocyte-derived DCs (mo-DCs). In the 
mouse, the expression of CD8  distinguishes two groups 
of cDCs with important effector subtypes [reviewed in  5 ]. 
Although CD8  is not expressed on human myeloid cells, 
they are thought to be functionally similar cDCs that can 
be distinguished by a mutually exclusive expression of 
CD1c/BDCA-1 and CD141/BDCA-3. The CD141/BDCA-
3-positive myeloid DCs are the less frequent subset that 
are functionally characterized by a high capacity to cross-
present antigen to CD8-positive T cells, suggesting that 
they are functional orthologs to the mouse CD8+ DC sub-
set  [12–16] . Human CD141/BDCA-3 positive DCs express 
the chemokine receptor XCR1  [15] , CD205/DEC205 (im-
portant for antigen uptake, trafficking and presentation), 
and the C-type lectin Clec9A (a receptor for necrotic cells) 
as in murine CD8-positive DCs  [17] . These molecules are 
thought to be associated with the enhanced capacity of 
this DC subset to cross-present antigen. 
 Follicular DCs (FDCs) are a specialized subset of DCs. 
They are not derived from the hematopoietic lineage and 
are found in the B cell zone of secondary lymphoid tissues 
 [18] . FDCs can restimulate both B cells and T cells and 
appear to help maintain immune memory in tandem 
with B cells. They do not express common myeloid or 
lymphoid markers and are positive for CD21.
 DCs in Non-Lymphoid Peripheral Tissues 
 The complexity of DC subsets increases as the cells un-
dergo phenotypic and functional adaptations in response 
to local tissue-specific microenvironments. The biology of 
DCs in non-lymphoid peripheral tissues is at present not 
well understood. Most studies of tissue DCs have been per-
formed in mouse models, and for many defined murine 
subsets the human counterparts remain to be identified  [7, 
19] . Both in mouse and in human, the best characterized 
organ with regards to the DC biology is the skin. It harbors 
the characteristic Langerhans cells which were the first 
DCs recognized as a distinct cell subset by the presence of 
Birbeck’s granules, now known as CD207/langerin ( fig. 1 ). 
Other peripheral organs with well-studied DC biology in-
clude the gut and lung [reviewed in  19 ]. The recognition of 
resident DCs in the human kidney occurred much later, in 
part due to the difficulty in tissue availability. 
 In the peripheral organs, DC subpopulations are 
thought to be largely derived from monocytes which infil-
trate the tissue and become polarized by the specific tissue 
microenvironment  [6] . As in the lymphoid tissues, periph-
eral organs contain at least two monocyte-derived myeloid 
subsets of DCs (mo-DCs). These are distinguished by the 
mutually exclusive presence of the marker CD103 or the 
chemokine receptor CX 3 CR1. These subsets are thought 
to exert different functions with the CD103-positive DCs 
(i.e. the less frequent subset) being largely responsible for 
generating CTL immunity and tolerance to tissue-asso-
ciated pathogens and antigens. The poorly migratory 
CX 3 CR1-positive DC subset is thought to help activate tis-
sue-infiltrating effector or memory T cells  [19, 20] . 
 DCs in the Human Kidney  
 Functional studies of DCs in human kidney, particu-
larly in the context of intrinsic renal diseases are limited 
and difficult to perform  [21–23] . Very little data are avail-
able from studies where these cell types have been ex-
tracted from human renal tissues. Therefore, at present 
the combination of markers provides only a suggestion as 
to the potential functional roles of these cells in the kid-
ney.
 The first description of major histocompatibility com-
plex (MHC) class I [human leukocyte antigen (HLA)-
ABC] and MHC class II- (HLA-DR) positive cells in the 
human tubulointerstitium was published in 1981  [24] . In 
this study, HLA-DR and HLA-ABC were detected in four 
kidneys not suitable for transplantation  [24] . These anti-
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 Fig. 1. DC development and DC subsets. This rough overview 
depicts DC development and subset specification. DCs derive 
from hematopoietic precursors (HSC) and develop along two 
branches: the lymphoid branch gives rise to the plasmacytoid 
CD303/BDCA-2- and CD304/BDCA-4-positive DCs (pDCs). 
The myeloid branch gives rise to the tissue Langerhans cells 
(CD207/langerin+), as well as the blood-resident monocytes and 
conventional myeloid DCs (CD1c/BDCA-1 positive, or CD141/
BDCA-3 positive). Recruited to peripheral tissues, DCs further 
diversify and may express a variety of markers including CD103 
and CD209/DC-SIGN. Thereby, the cDCs are further divided 
into the so-called type 1 and type 2 cDCs. Immunohistochemis-
try pictures illustrate the ‘lymphocytic’ morphology of CD303/
BDCA-2-positive cells, the stellate appearance of myeloid CD209-
positive DCs and the CD207-positive Langerhans cells. Immu-
nohistochemistry illustrates BCDA-2-positive pDCs in a biopsy 
with lupus nephritis (left); CD207 and CD209 are pictures from 
human tonsils.  
Table 1.  Human DC subsets, phenotypic markers and functional characteristics
DC subset Phenotypic markers Proposed function
Langerhans
cell 
myeloid marker positive [CD13+, CD33+],
CD207/langerin+, CD1a+, CD2+, CD45RO+ 
first immunologic barrier to the external 
environment
pDC myeloid marker negative [CD13–, CD33–], CD303/BDCA-2+, CD304/
BDCA-4+, CD2–, CD4+, CD45RA+, CD1c/BDCA-1–, CD141/BDCA-3–
high production of type I interferons 
(IFN/), antiviral response
Myeloid DC myeloid marker positive [CD13+, CD33+, CD11cdim], CD4+, CD45RO+
cDC type 1 CD1c/BDCA-1+, CD2+, CD303/BDCA-2–, CD141–,
(CD209/DC-SIGN), (CD14), (CD68), (CD103)
CD4 T cell priming
cDC type 2 CD141/BDCA-3+, CD2–, CD303–, CD1c–XCR1+, CD205/DEC205+, 
Clec9A+
cross-presentation ] CD8 T cell response
production of TGF- ] tolerance
mo-DC CD209/DC-SIGN+, (CX3CR1), (CD14), (CD68), (CD103) inflammation, tissue repair, homeostasis
T he list of markers represents a selection that currently best 
defines and distinguishes one DC subset from the other subsets. 
Markers in bold are characteristic for the indicated DC subset. All 
DCs are negative for lineage markers (CD3, CD19, CD20) and 
CD56. BDCA-1, -2, -3, -4 stands for blood dendritic cell antigen-1, 
-2, -3, -4 [11]. These markers were identified to distinguish indi-
vidual DC subsets in human blood. CD209/DC-SIGN is a marker 
of interstitial DCs. Markers listed in round brackets may be vari-
ably expressed on myeloid conventional and monocyte-derived 
DCs in non-lymphoid tissues.
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gens were found to be present on endothelium of glomer-
ular and peritubular capillaries. Additionally, cells in the 
tubulointerstitial space with a dendritic appearance were 
described to be positive  [24] . This important early step in 
the identification of renal DCs in human renal tissue was 
followed almost 10 years later by indirect evidence on 
DCs in inflamed kidneys  [25] . In a study on 69 patients 
with various forms of glomerulonephritis, cell lineage 
markers (for T cells, B cells, etc.) in addition to MHC an-
tigens HLA-DQ, DR and DP were localized and quanti-
fied. The number of HLA-DQ-positive cells outnum-
bered the sum of CD14- and CD20-positive cells. The 
authors concluded that this may indicate that DCs accu-
mulate in the tubulointerstitium during glomerulone-
phritis in the human kidney  [25] . Later, DCs were de-
scribed in the tubulointerstitium, and were positive for 
MHC class I (HLA-ABC) as well as MHC class II antigens 
(HLA-DR, DP and DQ)  [26] . The same group provided 
the first detailed description of these cells in human bi-
opsy material from patients with glomerulonephritis in 
1992  [27] . HLA-DR and CD1b were localized in a total of 
45 renal biopsies. In the controls, and in biopsies from 
a b
c d
 Fig. 2. CD209/DC-SIGN expression in re-
nal biopsies with lupus nephritis. Illustrat-
ed are biopsies with lupus nephritis stained 
for CD209/DC-SIGN (positive signal in 
black). Original magnification  ! 200 ( a , 
 b ),  ! 400 ( c ) and  ! 630 ( d ).  a A scattered 
population of CD209/DC-SIGN-positive 
cells within the well-preserved tubuloin-
terstitium (arrow).  b A very prominent ac-
cumulation of CD209/DC-SIGN-positive 
DCs.  c The glomerular tufts do not con-
tain CD209/DC-SIGN-positive cells, but a 
prominent periglomerular accumulation 
is present (arrow).  d At a higher magnifica-
tion, these cells demonstrate the typical 
morphology of DCs (arrow). 
 Dendritic Cells in Human Renal 
Inflammation  
Nephron Exp Nephrol 2011;119:e91–e98 e95
patients with glomerulonephritis but with well-preserved 
tubulointerstitium, no CD1b-positive cells were found 
 [27] . In contrast, in biopsies with active tubulointerstitial 
inflammation, CD1b-positive cells were found to be pres-
ent at sites of inflammatory cell accumulations. Even in 
this early study, the localization of DCs around injured 
glomeruli was strongly suggested. The periglomerular 
accumulation of DCs in human glomerulonephritis re-
flects the situation described in the mouse; however, the 
dense network of DCs demonstrated in the mouse was 
not as prominent in the human kidney  [27, 28] .
 Woltman et al.  [21] published the first study using 
more recent markers ( table 1 ) in a detailed analysis of fro-
zen tissues from pre-transplant biopsies (n = 21), IgA ne-
phropathy (n = 6) and renal allograft rejection (n = 6). 
This important paper described specific aspects of hu-
man renal DCs. Using the marker CD209/DC-SIGN, a 
population of tubulointerstitial cells with dendritic ap-
pearance was detected. The majority of these cells were 
also positive for the MHC class II antigen HLA-DR. Dou-
ble labeling with CD68 (previously used as a marker for 
macrophages) revealed colocalization with CD209/DC-
SIGN in the tubulointerstitium. Using double labeling for 
CD209/DC-SIGN and CD1c/BDCA-1, it was demonstrat-
ed that the majority of CD209/DC-SIGN-positive cells 
coexpressed CD1c/BDCA-1, but there was also a promi-
nent CD1c/BDCA-1 single positive cell population sug-
gesting a heterogeneous population of DCs in the tubu-
lointerstitium. Based on the current nomenclature, the 
DC subsets likely correspond to the mo-DCs (which 
should be the larger proportion) and the type 1 conven-
tional cDCs (which should account for the smaller per-
centage). Expression of CX 3 CR1 has been described to 
overlap with the pattern of CD68-positive cells in human 
renal inflammation, most likely corresponding in part to 
the mo-DCs  [29] . 
 CD303/BDCA-2 positive cells, morphologically re-
flecting pDCs, were also identified  [21] . In the small 
number of biopsies examined from patients with IgA ne-
phropathy and acute allograft rejection, the number of 
cells for all three markers was found to be increased, sug-
gesting an accumulation of DCs in the context of inflam-
mation. In normal kidneys, no CD208/DC-LAMP-posi-
tive cells were found, indicating the absence of mature 
DCs in well-preserved renal tissue  [21] . 
 We used a similar set of markers in a series of patients 
with various glomerular diseases  [22] . These included 55 
biopsies from patients with necrotizing glomerulone-
phritis, lupus nephritis, focal segmental glomeruloscle-
rosis, membranous nephropathy and minimal change 
disease. These samples were compared with biopsies 
without significant renal lesions. In diseases such as pro-
liferative lupus nephritis and necrotizing forms of glo-
merulonephritis, CD68-positive cells were found to ac-
cumulate in the tubulointerstitium and glomeruli. The 
pattern of the interstitial CD68-positive cells correspond-
ed to the general distribution of CD209/DC-SIGN-posi-
tive cells ( fig. 2 ). Using double labeling in combination 
with confocal microscopy, it was confirmed that these 
cells were positive for both markers  [22] . In contrast, the 
CD68-positive cells that accumulated in the glomerular 
tuft did not exhibit CD209/DC-SIGN staining on con-
secutive sections. Therefore, depending on the tissue 
compartment examined, the CD68-positive cells appear 
to represent different subtypes. The glomerular CD68-
positive cells were negative for CD209/DC-SIGN and ap-
pear to be macrophages, whereas in the tubulointersti-
tium, the majority of CD68-positive cells express CD209/
DC-SIGN and are more likely mo-DCs. The number of 
CD209/DC-SIGN- and CD303/BDCA-2-positive cells in-
creased in the tubulointerstitium in diseases with pro-
gressive interstitial injury and the area of CD209/DC-
SIGN expression was associated with renal function. 
CD208/DC-LAMP-positive mature DCs were present in 
low numbers in the tubulointerstitium of inflamed kid-
neys, but were very rare in control tissue confirming the 
results of Woltman et al.  [21] . CD207/langerin-positive 
cells were found in low numbers in the tubulointersti-
tium, but were common within the epithelium of collect-
ing ducts  [22] . 
 Fiore et al. [30] provided data on 21 patients with lupus 
nephritis and 12 healthy controls. The numbers of CD1C/
BDCA-1-, CD141/BDCA-3- and CD304/BDCA-4-posi-
tive cells were found to be significantly increased in the 
tubulointerstitium in biopsies with lupus classes III and 
IV. The number of CD208/DC-LAMP-positive mature 
DCs was again found to be small in this study. The same 
group recently provided data on 13 patients with lupus 
nephritis (five classes I–II, five classes III–IV, three class 
V)  [31] . The recruitment of ChemR23-positive pDCs 
(double labeling for BDCA-2) was demonstrated in the 
tubulointerstitium from patients with lupus nephritis 
 [31] . ChemR23 is a receptor for chemerin, which could be 
localized to tubular epithelial cells and lymphatic en-
dothelial cells in biopsies with lupus nephritis  [31] . In a 
transendothelial chemotaxis assay, the recruitment of 
pDCs by chemerin was demonstrated in vitro  [31] . 
 In contrast to the data describing DCs in the tubuloin-
terstitium of mouse and human kidneys, one study found 
a high number of pDCs in the glomeruli of patients with 
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lupus nephritis  [32] . These data await further confirma-
tion and have not been supported in two recent studies 
 [22, 30] . 
 Castellano et al. [23] demonstrated that CD1c/BDCA-
1-positive cells in the tubulointerstitium of biopsies with 
lupus nephritis also express C1q, a protein involved in the 
initiation of the classical complement pathway. This fea-
ture of renal DCs may be related to local complement ac-
tivation and modulation of the adaptive immune re-
sponse.
 The FDC morphologically represents an additional 
non-hematopoietic DC type  [18] . In renal biopsies from 
patients with lupus nephritis or vasculitis, organized fol-
licles, so-called tertiary lymphoid organs, develop in a 
subset of patients  [33] . These differentiated lymphoid or-
gans contain CD21-positive FDCs. The functional role of 
these structures as well as of the CD21-positive FDCs 
during the disease progress is currently poorly defined.
 DCs are also a prominent cell type found within the 
chronic inflammatory milieu of human renal cell carci-
noma (RCC), the most frequent neoplasia of the human 
kidney. The DCs were found to belong to the CX 3 CR1-
CD209 double-positive DC subset, and the majority of 
these DCs coexpressed macrophage markers (CD163, 
CD14). With regard to their phenotype, they appear to be 
similar to DC cell subtypes found in murine kidneys  [34] 
and human inflammatory kidney diseases  [22] . As ne-
phrectomy is the treatment of choice for RCCs, tumor- 
and control non-tumor-damaged kidney tissues were 
available for cell extraction that allowed detailed flow cy-
tometric analysis. This revealed that the CD209/DC-
SIGN-positive cells exhibit an activated phenotype with 
high expression of MHC class II antigens (HLA-DR), 
CD40, CD86 and CD80. Yet, the absence of CD83 and 
CD208/DC-LAMP suggests that they are not fully ma-
tured/licensed DCs. Although more functional studies 
are clearly warranted, initial studies suggest that these 
tumor-resident DCs may be involved in stalling an active 
immune response to the tumor and eliciting a tumor-
promoting cytokine and chemokine environment [35].
 Where Do We Go from Here? 
 It has become clear that prominent numbers of DCs 
are present in the tubulointerstitium of the normal hu-
man kidney and that DCs increase in number during re-
nal injury. At least three DC types can currently be dis-
tinguished in the human kidney. The two markers of 
myeloid DCs, CD209/DC-SIGN and CD1c/BDCA-1, sepa-
rate two cell populations, CD209/DC-SIGN and CD1c/
BDCA-1 double-positive and CD209/DC-SIGN-negative 
CD1c/BDCA-1-positive DCs. Additionally, there are 
pDCs with a lymphoid morphology expressing CD303/
BDCA-2. Based on their marker combinations, the ma-
jority of these cells appear to be immature. Unfortunate-
ly, except for our initial studies in RCC, there is at present 
no experimental information concerning the biologic 
role of DCs in the human kidney. 
 A prominent feature of the DC biology in renal tissues 
is their almost exclusive accumulation in the tubuloin-
terstitium, and not in glomeruli. DCs may be exposed to 
antigens from different sources. Many small proteins, 
which reach the tubulointerstitium through regular fil-
tration and reabsorption, should not produce an im-
mune response; rather, they may mediate an active state 
of tolerance with the help of DCs. In contrast, during as-
cending infections, and in unselective proteinuria, the 
DCs become exposed to various proteins not regularly 
present in the tubulointerstitium. In combination with 
cytokines and chemokines, this could induce matura-
tion and licensing of the DCs, resulting in rapid exit from 
the kidney and the potential activation of an acquired 
immune response in the local lymph nodes. An active 
propagation of the tubulointerstitial inflammation could 
help promote an ongoing destruction of this compart-
ment. The role of neolymphangiogenesis seen regularly 
in inflamed kidneys in the process will need to be stud-
ied further  [36] .
 The glomerular tuft is characterized by a low number 
of DCs and lymphocytes (B cells as well as T cells), while 
CD68-positive cells without markers of DCs accumulate 
during glomerulonephritis. These macrophages in com-
bination with activated mesangial cells are involved in 
the clearance of antigens accumulating in the mesangi-
um. An active acquired immune response could be del-
eterious in the glomerular tuft where antigens are con-
stantly accumulating and cleared within the mesangial 
area. Therefore, the presence of DCs in this area may be 
perilous, while macrophages with their non-immuno-
genic antigen clearance may represent a more suitable cell 
type. 
 The tubulointerstitium may be viewed as the ‘alarm 
system’ of the kidney where the right combination of sig-
nals is integrated into an acquired immune response, 
whereas the more delicate glomerulus remains an ‘im-
munoprivileged’ microenvironment to support the im-
portant functions of size-selective filtration and clear-
ance of mesangial proteins. 
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 Studies now need to proceed beyond the description of 
precise marker combinations to the functional descrip-
tion of renal DCs in the human situation. As materials 
from human kidneys are limited, it seems to be important 
that the groups in the field combine their future efforts 
which will help to increase the knowledge in this exciting 
area of research.
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